CD274 and non-small cell lung carcinoma: presented the outcomes analysis according to concomitant baseline medications (prior to ICI initiation) with putative immune-modulatory effects in a large cohort of 950 patients with metastatic NSCLC with a PD-L1 expression ≥50%, receiving first-line Pembrolizumab monotherapy; 595 patients treated with chemotherapy represented the control cohort [187].